CheckMate 649研究中纳武利尤单抗联合化疗对比化疗治疗晚期胃/胃食管结合部癌或食管腺癌患者的健康相关生活质量
CheckMate 649研究探索性分析显示,在晚期/转移性非HER2阳性胃/胃食管结合部癌或食管腺癌患者中,纳武利尤单抗联合化疗对比化疗未增加患者报告的症状负担,在PD-L1 CPS≥5人群中改善FACT-Ga总分、GaCS和EQ-5D视觉模拟量表,并降低症状和明确HRQoL恶化的风险。
要点
- 纳武利尤单抗联合化疗对比化疗未增加患者报告的症状负担
- CPS≥5人群中联合组FACT-Ga总分、GaCS和EQ-5D VAS较基线改善优于化疗
- 联合组降低症状恶化风险并延长至明确恶化时间,HRQoL多数指标HR<1
核心结论
- 对比化疗,一线纳武利尤单抗联合化疗在晚期/转移性非HER2阳性GC/GEJC/EAC患者中显示治疗期间HRQoL稳定或更优,并降低明确HRQoL恶化风险。
研究设计与样本
- CheckMate 649研究为探索性患者报告结局分析,患者(N=1,581)按1:1随机分配至纳武利尤单抗联合化疗或化疗。
- PRO分析人群为基线及至少1次基线后评估的随机分配患者(n=1,360),使用EQ-5D和FACT-Ga(含FACT-G和GaCS)评估HRQoL,GP5条目评估治疗相关症状负担。
- 采用重复测量混合模型评估HRQoL纵向变化,并进行至症状或明确恶化时间分析。
主要发现
- PRO分析人群(n=1,360)中,治疗期间问卷完成率大多>80%。
- 对比化疗,纳武利尤单抗联合化疗未增加患者报告的症状负担。
- CPS≥5人群中,纳武利尤单抗联合化疗对比化疗在FACT-Ga总分、GaCS和EQ-5D视觉模拟量表上自基线改善的平均变化更大,总体PRO分析人群结果相似。
- 在CPS≥5和所有随机分配人群中,基于FACT-Ga总分和GaCS,纳武利尤单抗联合化疗对比化疗降低症状恶化风险;至明确恶化时间更长,且EQ-5D和多数FACT-Ga指标明确HRQoL恶化风险降低(HR[95%CI]<1)。
关键数值与推荐
- PRO分析人群n=1,360,患者总数N=1,581;问卷完成率大多>80%。
- CPS≥5人群中,FACT-Ga总分、GaCS和EQ-5D VAS的改善变化纳武利尤单抗联合化疗优于化疗;总体PRO分析人群结果相似。
- CPS≥5和所有随机分配人群中,FACT-Ga总分和GaCS的症状恶化风险降低,EQ-5D和多数FACT-Ga指标的明确恶化HR[95%CI]<1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs). METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≥5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≥1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted. RESULTS: In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of ≥5; results were similar for the overall PRO analysis population. In CPS ≥5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1). CONCLUSION: Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.
引用
- Moehler M, Xiao H, Blum SI, et al. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023. PMID: 37713657. doi:10.1200/JCO.23.00170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。